期刊文献+

sST2对不同类型慢性心力衰竭预后的预测价值 被引量:13

下载PDF
导出
摘要 目的探讨可溶性生长刺激表达基因2蛋白(solubility growth stimulation expressed gene 2,s ST2)对不同类型慢性心力衰竭预后的预测价值。方法选取2018年3月至2019年1月在东莞市第五人民医院心内科住院的符合慢性心力衰竭(CHF)诊断标准的患者177例。依据左心室射血分数(LVEF),把心力衰竭分为射血分数降低型HF(HF with reduced ejection fraction,HF-r EF)组(LVEF <40%) 47例、射血分数中间值型HF(HF with mid-range ejection fraction,HF-mr EF)组(40%≤LVEF≤49%) 49例、射血分数保留型HF(HF with preserved ejection fraction,HF-p EF)组(LVEF≥50%) 81例三组。采用酶联免疫吸附法测定血浆s ST2水平。采用受试者工作特征曲线(receiver operator characteristic,ROC)计算不良事件最佳辅助诊断切点值并计算曲线下面积。采用Logistic回归方程校正混杂因素分析s ST2水平对1年后不良事件发生风险的影响。结果三组间性别、糖尿病患病率、收缩压(SBP)、舒张压(DBP)、LVEF、β-受体阻滞剂、地高辛、螺内酯用药史、s ST2、低密度脂蛋白胆固醇(LDL-C)差异有统计学意义(P<0.05)。HF-mrEF组s ST2水平显著高于HF-pEF组(P<0.05),HF-rEF组s ST2水平显著高于其他两组(P<0.05)。Logistic回归分析显示,男性[OR(95%CI):2.23(1.37~2.54)]、SBP[OR(95%CI):1.38(1.19~1.60)]、DBP[OR(95%CI):1.41(1.27~1.57)]、糖尿病[OR(95%CI):1.41(1.26~2.13)]、高s ST2[OR(95%CI):1.14(1.07~2.65)]可增加CHF患者不良事件的发生风险。结论 s ST2可以是不同类型CHF患者发生不良事件的独立危险因素之一,一般s ST2水平越高者预后越差。
出处 《心脑血管病防治》 2019年第6期561-563,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金 广东省东莞市社会科技发展局项目(编号:2018507150251298)
  • 相关文献

参考文献7

二级参考文献69

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:90
  • 2叶任高 主编.内科学:第5版[M].北京:人民卫生出版社,2001.824.
  • 3Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 4Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 5Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 6Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 7Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 8Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 9Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.
  • 10Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J, 1999, 14(2) : 270-274.

共引文献4941

同被引文献100

引证文献13

二级引证文献60

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部